Merck KGaA Finds The Right Home For Disease-Modifying OA Agent In Novartis
Licenses Nanobody M6495 To Swiss Firm
Novartis has added an anti-osteoarthritic Nanobody, M6495, to its growing pipeline of candidates for the condition, in a €450m agreement with Merck KGaA that sees the latter deliver on its plans to find new homes for its osteoarthritis pipeline.
You may also be interested in...
Last week, the Swiss major gave a glimpse into the next wave of innovation coming out of its labs in key areas such as osteoarthritis, pancreatic cancer and food allergy. Scrip has been taking a detailed look at the highlights.
Long touted as one of the drugs to watch in the Swiss giant's pipeline, iscalimab's chances of replacing tacrolimus as the standard of care preventing organ rejection in transplant patients have been dealt a hefty blow after a Phase II trial failure.
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.